(Q34837632)

4 August 2017

1 reference

title

Identification of new therapeutic targets for prevention of CNS inflammation (English)

1 reference

4 August 2017

0 references

Trevor Owens

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Expert Opinion on Therapeutic Targets

4 August 2017

published in

1 reference

4 August 2017

volume

6

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

203-215

1 reference

Axonal transection in the lesions of multiple sclerosis

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Immunologic therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Matrix metalloproteinases and diseases of the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Metalloproteinases in biology and pathology of the nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Innate and adaptive immune responses can be beneficial for CNS repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Identification of autoantibodies associated with myelin damage in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Thalidomide as an emerging immunotherapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Genetic models for CNS inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Exacerbations of multiple sclerosis in patients treated with gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Interferon-gamma protects against cuprizone-induced demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Interferon gamma gene expression in sensory neurons: evidence for autocrine gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Anti?tumor necrosis factor therapy abrogates autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Bone marrow-derived elements in the central nervous system: an immunohistochemical and ultrastructural survey of rat chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Turnover of resident microglia in the normal adult mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Down-regulation of the macrophage lineage through interaction with OX2 (CD200)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Migration of exogenous immature hematopoietic cells into adult mouse brain parenchyma under GFP-expressing bone marrow chimera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Multiple sclerosis: magnetization transfer MR imaging of white matter before lesion appearance on T2-weighted images

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.6.2.203

21 January 2018

Identifiers

DOI

10.1517/14728222.6.2.203

1 reference

4 August 2017

1 reference